Availability of Effective Evidence-Based Symptomatic Treatments for Cluster Headache in the EU Countries— A Survey of the European Headache Alliance and European Headache Federation

Aims: To assess the reimbursement options and accessibility of three effective medicines for cluster headache (CH) (subcutaneous sumatriptan, oxygen, and zolmitriptan spray) across the European Union (EU). Methods: A brief survey investigating the availability of symptomatic treatments for CH was sent by email in January 2017 to at least one headache specialist for every single country in the EU. Results: The questionnaire was completed by 26 headache specialists (93% of the EU countries, representing 99.75% of the European population) and by 10 CH patients representative of patient organizations. Oxygen was reimbursable for 63% of the CH population. Oxygen device was reimbursable for 50% of the CH EU population. Subcutaneous sumatriptan was reimbursable for 66% and was accessible without restrictions for 45% of the CH EU population. Zolmitriptan spray was reimbursable for 23.7% and accessible without restrictions for 30.9% of the CH EU population. Conclusion: Only 47% of the EU population had unrestricted access to effective CH treatments, with unacceptable inequalities between eastern countries and the rest of Europe. Headache societies and patient associations should pressure European and national health authorities to improve the availability of effective symptomatic treatments for CH.

access to care; cluster headache; oxygen; sumatriptan; symptomatic treatment

1. Nesbitt AD, Goadsby PJ. Cluster headache. BMJ 2012;344: e2407.

2. Rozen TD, Fishman RS. Cluster headache in the United States of America: Demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache 2012;52:99–113.

3. Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology 2010;75:463–473.

4. May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006;13:1066–1077.

5. Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: The American Headache Society Evidence-Based Guidelines. Headache 2016;56: 1093–1106.

6. Lademann V, Jansen JP, Evers S, Frese A. Evaluation of guideline-adherent treatment in cluster headache. Cephalalgia 2016;36:760–764.

7. Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: A randomized trial. JAMA 2009;302:2451–2457.

8. Treatment of acute cluster headache with sumatriptan. The Sumatriptan Cluster Headache Study Group. N Engl J Med 1991;325:322–326.

9. Evers S, Rapoport A, International Headache Society. The use of oxygen in cluster headache treatment worldwide—A survey of the International Headache Society (IHS). Cephalalgia 2017;37:396–398.

10. Pauwels K, Simoens S, Casteels M, Huys I. Insights into European drug shortages: A survey of hospital pharmacists. PloS One 2015;10:e0119322.

11. Folino-Gallo P, Palazzo F, Stirparo G, De Filippis S, Martelletti P. Price differentials of oral triptans in eight European Union countries. J Headache Pain 2003;4:s67–s69.

12. Cherny NI, Baselga J, de Conno F, Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: A report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 2010;21:615–626.

13. Vranken MJ, Lisman JA, Mantel-Teeuwisse AK, et al. Barriers to access to opioid medicines: A review of national legislation and regulations of 11 central and eastern European countries. Lancet Oncol 2016;17:e13–e22.

14. Linge-Dahl L, Vranken M, Juenger S, et al. Identification of challenges to the availability and accessibility of opioids in twelve European countries: Conclusions from two ATOME six-country workshops. J Palliat Med 2015;18:1033–1039.

15. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs, 2018. Last updated 13 December, 2018. https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ ddd_index/. Accessed 23 April, 2019.

16. International Narcotics Control Board. Single Convention on Narcotic Drugs, 1961. Vienna: International Narcotics ControlBoard, 2005. https://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf. Accessed 23 April, 2019.

17. World Health Organization. Narcotic & Psychotropic Drugs. Achieving Balance in National Opioids Control Policy: Guidelines for Assessment. Geneva, Switzerland: World Health Organization, 2000. http://apps.who.int/medicined-ocs/pdf/whozip39e/whozip39e.pdf. Accessed 23 April, 2019.

18. Larue F, Fontaine A, Brasseur L. Evolution of the French public’s knowledge and attitudes regarding postoperative pain, cancer pain, and their treatments: Two national surveys over a six-year period. Anesth Analg 1999;89:659–664.

19. République Française. Loi n° 2002-303 du 4 mars 2002 relative aux droits des malades et à la qualité du système de santé. https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=-JORFTEXT000000227015. Accessed 23 April, 2019.

20. Garcia del Pozo J, Carvajal A, Viloria JM, Velasco A, Garcia del Pozo V. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol 2008;64:411–415.

21. Solomon GD. Reducing the cost of headache medication. Curr Pain Headache Rep 2009;13:227–230.